Working at the NKI
Find out more about working at the Netherlands Cancer Institute
Throughout the year we have vacancies for group leaders,
postdoctoral fellows, Ph.D. students and technicians. Also, for
masters students and student technicians we offer rotation
projects. Below we have listed the current vacancies. If you are
interested in a position at our institute, please contact one of
our group leaders.
We offer a stimulating and interactive research environment, state of the art facilities, a competitive salary (including possibilities for additional tax-reduction for non-Dutch employees) and housing facilities in the vicinity of the Institute. Researchers at the Netherlands Cancer Institute have no teaching obligations.
On the Education page you can see which vacancies are currently available for Ph.D. students and postdocs.
The NKI has a sizeable postdoc community of approximately 180 scientist. It is a highly international community with fifty percent of postdocs hailing from 28 various nations, besides the Netherlands. To support this diverse community, an active postdoc committee, postdocs@NKI, was started in 2011.
Click here to read more about out aims and activities.
Vacancy Postdoctoral Researcher
PhD Student Biomarker discovery for prostate cancer treatment response
Vacancy PhD project on Myxoid Liposarcoma (MLS)
Vacancy Graduate Student
Vacancy Postdoc In vivo cancer drug target discovery screens exploiting T-cell immunity
Vacancy PhD Student Image-guided navigation surgery in rectal cancer
Vacancy Postdoc Developing improved immunotherapy for melanoma using advanced antibodies
Vacancy PhD Student Physics - Biomedical engineering/medical physics
Facts & figures
- Carcinogen laboratory
- Digital Microscopy facility
- Flow cytometry facility
- Mouse clinic - transgenic core facility
- Radionuclides centre
- Protein facility
- Technology Transfer Office
- Electron microscope facility
- Genomics Core Facility
- Robotics and Screening Center
- Mouse Clinic Intervention unit
- Research IT
- Peptide facility
- Molecular Pathology & Biobanking Core facility
- Biostatistics Center
- Tech transfer: What and why?
- About us
- Research-related Contracts
- Reagents for licensing
- Technologies for licensing
- Spin-off companies from the NKI
- News and events
- Success stories originating from NKI research
- Course Material
- Supplementary Material
- Data Analysis
- NRSC Staff
- Postdoc Dean
- Postdoc training program
- Events and initiatives
In cancer research we use a lot of dangerous compounds.
The carcinogen lab is a research facility where carcinogenic,
mutagenic and reprotoxic compounds can be stored and were these
compounds can be handled under special safety conditions.
The carcinogen laboratory is mainly used to prepare solutions using chemicals in a powder form. The chemicals can be weighted in a fume hood, dissolved and then taken out of the carcinogen laboratory for use in experiments. The lab is under-pressured, has a higher than normal ventilation fold and is equipped with two safety hoods.
Researchers can get instructions on how to work with carcinogens and about safety aspects. The instructions and the information is given by one of the supervisors of this facility. They also make sure everything is working properly and is kept clean and tidy.
Click here for more information about the Carcinogen laboratory
Digital Microscopy facility
The Digital microscopy facility offers high level and broad range light microscopy facilities to all researchers in the Netherlands Cancer Institute. The equipment consists of nine microscopes: four confocals, four wide-field ones and a TIRF setup. Together they form a complementary set of instruments. Live cell imaging capabilities are implemented on three confocals, two wide-field microscopes and the TIRF setup. The staff provides extensive support to users by e.g. introducing them to the systems, offering help and advise in using the microscopes and taking care of image archiving. Importantly, continuous quality control of the instruments, in its broadest sense, is provided as well.
Click here for more information about the Digital Microscopy facility
Flow cytometry facility
Flow cytometry is a powerful tool to quickly characterize millions of individual cells and, if needed, sort the cells based on their characteristics. The analysis is based on the size and complexity of the cell, in combination with the presence of fluorescence signals in the form of antibodies, fluorescent proteins or other dyes. The Flow cytometry facility gives researchers access to a variety of cell analysers and sorters. The dedicated operators of the flow cytometry facility give training, technical support with experiment setup, take care of the maintenance of the equipment and perform sorting experiments.
Click here for more information about the Flow cytometry facility.
Mouse clinic - transgenic core facility
The Netherlands Cancer Institute has a very strong history in the generation and validation of mouse models of human cancer. Many conditional mouse strains for tumor suppressor alleles have been generated here and are routinely used worldwide. In that context, the Transgenic core facility accommodates all activities required to generate genetically modified animals as well as cryopreservation.
Click here for more information about the Mouse clinic - transgenic core facility.
The Radionuclides centre (RNC) is the facility for researchers who want to perform their radioactive experiments in the Netherlands Cancer Institute. This centre has several containment levels (B, C and D-level) in which a range of experiments can be performed. Also, the facility provides regular courses (Radiation Protection level 5B) for people who want to use radioactivity during their experiments. The staff of the RNC provides help and advice on various aspects of radioactivity.
Click here for more ionformation about the Radionuclides centre.
The Protein facility of the Netherlands Cancer Insitute provides support at all levels of protein research, including the production and purification of proteins, biophysical characterization and high-throughput protein crystallization screening. The facility offers know-how, (biological) tools and access to dedicated equipment to assist both in routine- as well as more challenging projects.
Click here for more information about the Protein facility.
Technology Transfer Office
The NKI has a mission to beat cancer and performs world-beating research to increase our understanding of this disease. The knowledge that is gained in this way sometimes opens avenues for development of e.g. novel treatments or new diagnostic tests.
To achieve its mission, NKI actively collaborates with private companies that have the knowledge and the means to develop products based on research results obtained at our institution.
Contact: TTO at +31 (0)20 512 1999 or via email@example.com.
Electron microscope facility
The Electron microscope facility enables researchers at the Netherlands Cancer Institute to look at cellular structures and protein complexes at high magnification.
The facility has two electron microscopes. Since 1990 we have a Philips CM10 electron microscope operating with acceleration voltages of 40-60-80-100 kV fitted with a tungsten emitter. This electron microscope still makes use of negatives that are developed and printed by our photographer Nico Ong. Since 2001 we have a FEI Tecnai 12 G2 Biotwin 120 kV microscope fitted with a LaB6 emitter and an Eagle 4Kx4K fiber-optically coupled, TEM CCD camera. This microscope is suited for cryoEM and tomography. It has integrated FEI Explore 3D and Inspect 3D software for aligning and reconstructing tomogram series.
The dedicated EM operator maintains the microscopes and performs the sample preparation and acquisition of data.
Genomics Core Facility
The Genomics Core Facility offers Next Generation Sequencing services using Illumina equipment (HiSeq2000 and MiSeq). Next generation sequencing is a very versatile technology that has applications in many different experiments. Sequencing data can be used to discover mutations in the exome or smaller targeted gene sets, find genome wide copy-number variations, analyze RNA expression levels or read complete inventories of small RNA or the results of functional genetic screens. In addition to the wet lab part the facility also provides data storage and bioinformatics support and maintains access to several commercial tools like Ingenuity and Nexus. Investigators have the option to hand in cells, tissue, tumor, RNA, DNA or prepared sequence libraries for analysis.
Click here for more information about the Genomics Core Facility.
Robotics and Screening Center
The Netherlands Cancer Institute Robotics and Screening Center (NRSC) provides advanced technology platforms to perform large scale screening projects using cell based- or biochemical read-outs. The NRSC provides acces to large collections of functional genomic screening tools including genome wide siRNA, shRNA and CRISPR collection. In addition, the NRSC has a genome wide cDNA/ORF collection and numerous small molecule collections. These screening technologies enable researchers to discover novel gene functions, to unravel molecular pathways and mechanisms, to discover novel drug targets and to support the identification of small molecules both for biological tools and novel drug leads. The NRSC provides technology and infrastructure for medium to high throughput applications, provides support and expertise for automated cell and non-cell based assays and is used for the development, production and maintenance of large screening reagent collections.
Click here for more information about the Robotics and Screening Center.
Mouse Clinic Intervention unit
Our goal is to use advanced mouse models as surrogate cancer patients to identify and validate targets that can be exploited by anti-cancer therapy. Various approaches to treat cancer with classical chemotherapy, targeted inhibitors, immunotherapy, radiotherapy or combinations thereof are ongoing. Special emphasis is given to target the clinical handicap of therapy escape. To support these activities, a dedicated preclinical intervention and imaging unit facilitates accurate measurement of tumor growth, metastasis formation, and therapy response in several mouse models of human cancer.
Click here for more information about the Mouse Clinic Intervention unit.
The Research IT facility has the mission to develop solid and sustainable Information Technology (IT) infrastructure to provide state-of-the-art IT services to NKI-AvL researchers.
To see the services we offer and our team, click here
The Peptide facility synthesizes peptides for researchers. The
is done on a small scale (2 micromole for screening purposes) and up to
millimole scale. Long peptides up to 100 amino acids (ubiquitine for instance) can be synthesized and all kind of derivatives are possible (biotinylation,
phophorylation, dyes etc.). Quality check and purification of the peptides is
also part of the service.
Click here for more information about the Peptide facility.
Molecular Pathology & Biobanking Core facility
The Core Facility Molecular Pathology & Biobanking (CFMPB) registers, coordinates, assists and facilitates research involving archived human/patient material. This concerns all research using NKI-AVL Biobank material from the department of Pathology (the FFPE tissue archive and frozen tissue bank) and the department of Clinical Chemistry (the serum and blood biobank). The facility provides professional expertise, appropriate sample and tissue based experimentation, and implements optimally controlled medical-ethical issues according to the 'Code of conduct'.
Click here for more information about the Molecular Pathology & Biobanking.
Biostatistics is a key component in planning, conducting and analysing studies in biomedical cancer research, including epidemiology. In order to employ state-of-the-art statistical approaches, investigators and doctors from the Institute and the hospital may contact the Biostatistics Center for statistical advice. We are involved in developing and implementing various methods to cover a wide range of topics including the design and analysis of epidemiologic studies and clinical trials, the identification of prognostic and predictive biomarkers, sample size calculations, risk prediction, as well as animal and in vitro experiments. The Biostatistics Center also conducts the annual one-week Basic Medical Statistics course, attended by more than 50 graduate students.
Click here for more information about the Biostatistics Center.
Tech transfer: What and why?
Academic research organizations typically excel at producing and isseminating new knowledge. Scientific breakthroughs draw interest and enthusiasm from the research community when they are announced at an academic conference or published in a scientific journal. Many potential benefits are likely to remain untapped, however, if no further investment is made in turning such breakthroughs into products. Because academic research organizations typically lack the knowledge and resources that are required for product development, most often such investment requires the involvement of companies or investors that work on a commercial basis.
Valorization - creating economic and social value through the application of academic research results - is becoming increasingly important and should be encouraged, always with due respect to the freedom of the academic researcher. The Netherlands Cancer Institute (NKI) is an international center of innovative cancer research and tries to maximize the potential impact of its research results. It does so by allowing the commercial use of such results and specialist knowledge to companies who have the commitment and resources to transform these into products and services that improve diagnosis, treatment and/or quality of life for cancer patients through a process called 'knowledge and technology transfer'.
Effective Technology transfer requires a combination of skills, which is reflected in the backgrounds of the various people from the NKI TTO team:
Hylke Galama, LLM
Phone: +31 20 512 6094
Hylke has obtained her degree in Law at the Vrije Universiteit in Amsterdam and she performed her masters on IP and Law. In 1998 she started working at IBM and during the last seven year at IBM she worked as a negotiator at IBM legal, where she has obtained extensive knowledge and expertise in contracting and negotiating on a national and international level. She started her function as legal counsel at the Netherlands Cancer Institute in August 2009.
Phone: +31 20 512 1999
Frank joined the TTO of NKI in June 2006 and has a background in (financial) administration. He handles the incoming and outgoing research and commercialization agreements and deals with MTA requests from other academic research institutes. Importantly, Frank is also instrumental in monitoring licensing obligations and royalty reporting and processes the financial administration of the TTO.
Senior business developer
Phone: +31 20 512 6071
Marije Marsman studied Medical Biology at the University of Amsterdam (1999). In 2005 she obtained her PhD from the University of Leiden on research performed at the Netherlands Cancer Institute. She continued to work for the Netherlands Cancer Institute as a Postdoc until 2006. During this period she developed expertise in the main areas of molecular biology, cell biology, microbiology and biochemistry. In 2007 Marije worked as a Patent Information Specialist at Organon. Until 2009 Marije worked as a Trainee Patent Attorney at Vereenigde. Prior to her employment at the NKI Technology Transfer Office (TTO) Marije worked as a business developer for the LUMC-TTO LURIS. In her job as a Business Developer at the NKI-TTO Marije is responsible for the commercialization/valorization of NKI's Intellectual Property.
Stephanie de Meza, MA
Phone: +31 20 512 8240
Stephanie obtained her master's degree in Private Law at the University of Amsterdam in 2013. She also holds a degree in law (HBO-Rechten) from the University of Applied Sciences in Leiden (2005-2009) and a Bachelor's degree in law from the University of Amsterdam (2009-2012). The combination of legal know-how and practical experience gained from her different studies gives her a unique perspective in the daily goings-on at the TTO. Stephanie has experience with legal and administrative duties thanks to internships and a job as an administrative assistant. As paralegal of the TTO Stephanie handles incoming MTAs, consultancy agreements, NDAs, sponsor agreements and also lends a helping hand in other administrative duties.
Anje Raven, MSc
Technology Transfer Associate
Phone: +31 20 512 6280
Anje studied Biology and Medical Laboratory Research at the
Hanze Hogeschool in Groningen (2004-2008). Thereafter started the
master Biomedical Sciences in Leiden and finished her management
master in June 2012. After doing an internship at technology
transfer office (TTO) of Leiden University (LU) and Leiden
University Medical center (LUMC), got a position at the TTO of the
Netherlands Cancer Institute (NKI) in October 2012 and since April
2013 holds a position as business developer at the TTO of the
Her responsibilities include commercialization of research materials (mostly antibodies, cell lines and mice), support in arranging collaboration agreements, organizing company visits and support in managing the patent portfolio of the NKI.
Koen Verhoef, PhD
Phone: +31 20 512 1998
Koen holds a PhD in molecular virology and started his career in tech transfer when he joined the Medical Research Council in 2001 as a technology transfer manager (through its London-based subsidiary company MRC Technology). Upon return to the Netherlands, Koen founded the TTO at VU University medical centre in Amsterdam - which later expanded its activities to also include VU University - where he was responsible for IP and licensing until moving to NKI in May 2009. Koen served as a board member of ASTP-Proton, the European professional association for technology transfer, from 2010 - 2014 and is a Registered Technology Transfer Professional (RTTP).
Collaborative projects, consultancy and contract research
NKI researchers and clinicians frequently collaborate with companies or other research organizations in research projects in which they have an academic interest.
They may on occasion also provide services at the request of companies or other organizations as long as these services compatible with the mission of NKI. These services may take the form of professional advice (consultancy) or or may involve contract research in areas in which NKI has particular expertise or resources that are not readily available elsewhere.
The TTO of the Netherlands Cancer Institute (NKI) supports researchers in negotiating, drafting and monitoring the agreements that are concluded around these research projects and services.
For information on collaborative and/or contract research
opportunities and access to expertise for consultancy work at NKI,
firstname.lastname@example.org or phone +31 20 512 1999
Other research-related agreements for:
- sharing of Research Materials -> Material Transfer Agreements (MTAs)
- sharing of confidential information -> Confidential Disclosure/Non-disclosure Agreements (CDAs/NDAs)
- access to patient material obtained at NKI -> Sample Transfer Agreements (STAs, in the context of a collaboration only)
- research involving cancer patients -> Clinical Research Agreements (CTAs)
Reagents for licensing
Companies can gain access to Research Materials developed at NKI for commercial use:
- Transporter proteins/pharmacokinetic studies
- Stem cells
- Mouse models of cancer
- Knock-out mice
- Transgenic mice
Technologies for licensing
The opportunities will follow soon...
Spin-off companies from the NKI
News and events
- July 2014: NKI concludes a collaboration agreement with Bionovion revenue from commercialisation activities in 2013 increases to 4,27 M €, around 5,7% of the annual research budget of NKI
- June 2014: NKI partners with Pivot Park Screening Centre (Oss, NL) and Leiden University in the creation of the 'Cancer Drug Discovery
- Initiative' (CDDI). This initiative aims to develop small molecule drugs against novel cancer targets and to partner these molecules with industry for further preclinical and clinical development, May 2014: NKI concludes a collaboration and license agreement with Forma Therapeutics
- 1 October 2014: workshop 'Intellectual property in research' (post-doc committee), NKI, Amsterdam
Success stories originating from NKI research
- Mammaprint: prognostic test determining the chance of recurrence of breast cancer after surgery
- Image-guided radiation therapy: revolutionizing radiotherapy through increased accuracy and reducing damage to healthy tissue
- CA 15-3 test: monitoring of breast cancer therapy response and early recurrence
Dr. Michael Hauptmann received a PhD in Statistics from the University of Dortmund, Germany, in 1999. In the same year, he joined the Biostatistics Branch of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute in Bethesda, Maryland, U.S.A., as a postdoctoral fellow, and became a tenure-track investigator in 2004. Since 2006, Dr. Hauptmann is a senior statistician at the Netherlands Cancer Institute in Amsterdam, The Netherlands.
Dr. Katarzyna Jozwiak obtained a Master's degree in Applied Mathematics from Delft University in 2008, and in Econometrics and Computer Science from the University of Zielona Góra, Poland, in 2009. As a graduate student in Applied Statistics at Utrecht University, she investigated optimal designs of trials with discrete-time survival endpoints and completed her PhD in 2013. After a brief period as software developer at Utrecht University, Dr. Jozwiak joined the Netherlands Cancer Institute in Amsterdam, where she is a statistical consultant for clinicians and other researchers of the Institute and the Antoni van Leeuwenhoek hospital.
Dr. Wilma Heemsbergen studied Biomedical Health Sciences at the Radboud University in Nijmegen (1988-1995). In 2008, she obtained a Ph.D. degree at the Medical Faculty of the University of Amsterdam. Her thesis was about the risks and benefits of modern conformal radiation treatment in prostate cancer. Since 1998, Dr. Heemsbergen works at the Department of Radiotherapy, and also at the Department of Epidemiology and Biostatistics since 2009. She is registered since 2008 as a senior researcher in the field of epidemiology.
Dr. Patrycja Gradowska obtained her PhD from the Department of Applied Mathematics of Delft University of Technology in 2013. For her dissertation, she developed mathematical methods and tools for assessing and managing human health benefits and risks from chemicals in food. She then became a postdoctoral researcher at the Netherlands Cancer Institute evaluating radiation-related risk of cancer following pediatric computed tomography examinations within the EPI-CT consortium. As part of her work, Dr. Gradowska also provides statistical advice to doctors and other researchers in the Institute and the Antoni van Leeuwenhoek hospital.
For people inside the AVL or NKI: Go to the Leerportaal and register for the course.
For people from outside the institute: Apply for registration by submitting your CV and a brief description of what you expect from the course and what type of data you plan to analyze in the future to Patty Lagerweij at email@example.com. Please also include in your application whether or not
- you want to participate in the half-day "Introduction to SPSS",
- you are able to bring your own laptop,
- you are a Ph.D. student of the OOA (Onderzoeksschool Oncologie Amsterdam) or an employee of the NKI-AvL.
If you are a member of the OOA, you can also register via the registration form on the OOA website.
For administrative questions, call Patty at 020-5126973. For questions related to the content of the course, you can contact Michael Hauptmann at 020-5121047.
Fee The course is free of charge for employees of the NKI-AvL and for Ph.D. students of the OOA (Onderzoeksschool Oncologie Amsterdam). For all others, the fee is EUR 700 including the "Introduction to SPSS", course materials and coffee/tea. The fee does not include meals.
All the course materials (slides, data sets, exercise sheets,
suggested reading, etc.) can be downloaded by sessions
(S) and practicals (P). Please note that the website will be
updated regularly, and contents may slightly change. Handouts of
the most recent version of the slides will be provided before each
session, and exercise sheets will be provided before the
During sessions, the basic concepts will be presented and illustrated with examples. During the computer practicals, you will work on data analysis exercises while faculty is present to assist you and answer any questions you might have. At the end of each day, the exercise sheets on the website will be replaced by sheets with suggested answers.
Sessions will be held in the Piet Borst Auditorium (PBA) and practicals in room Z4 (next to PBA). Please bring your own laptop for the SPSS introduction (if you attend) and the practicals. All data sets on the website below (scroll down to the "Data sets" section) should have been downloaded to the laptop. For those who indicated not having a laptop, we will provide one for the practicals.
We recommend preparing for the course by reading the papers accompanying some of the data sets (scroll down to the bottom), as well as papers or book chapters provided under ''Supplementary Material''.
Click here to find all the course material.
The supplementary material can be useful resources for further reading. The list will be updated before the start of the next course.
Click here to find the supplementary material.
The NRSC has several large collections of functional genomic tools (e.g. RNAi reagents and ORF collections) and small compound libraries available for researchers to use in high throughput screens. For functional genomic screens, these include the Thermo Scientific Dharmacon full genome siRNA library (human and mouse), the NKI shRNA collections (human and mouse), the Mission TRC shRNA collection (TRC 1.0, 1,5 and 2.0, human and TRC 1.0 mouse) and the CCSB-Broad lentiviral expression library. For these collection we also have customized gene subsets available e.g human kinome, DNA damage collection and epigenetic modifiers. For drug screens, our compound collections include the LOPAC library, a pharmacologically active compound set, kinase and phosphatase inhibitor sets and several targeted sets for oncology research.
The Netherlands Cancer Institute Robotics and Screening Center (NRSC) uses al kinds of smart equipment such as robotics liquid handling workstations, platforms, handlera and analysers.
Click here for more detailed information about the equipment of the NRSC.
Pooled shRNA screen analysis
We provide analysis of large scale pooled shRNA screens for which deep sequencing data is generated. We have developed a pipeline in which quality control plots, correlation between replicates and a hierarchical clustering of the samples are generated. Based on this quality control information a decision is made for the inclusion and exclusion of replicate samples from further analysis. After normalization and statistical analysis, a scoring for each individual shRNA is produced. Using different analysis methods and criteria, genes are selected as hits for further validation and follow-up.
Synergy screen analysis
At the NRSC we have generated an assay and an analysis tool to calculate synergy for two compounds. The assay is performed in 384 well plate format and allows for up to six separate synergy experiments at once. Per synergy experiment a compound in 5 concentrations is done against the second compound in 5 concentrations, resulting in a 5 * 5 matrix. Synergy is calculated by subtracting measured data from expected data, based on the dose response curves and the Loewe formula. The output of the synergy analysis provides a synergy score based on all 25 cells in an experiment.
Compound screen analysis
Data from compound screens performed at the NRSC is stored in the Screensaver database. The database provides a web-interface for the user to view their screens. In the screen view the library information is automatically linked via plate-well position. In Screensaver plate normalization can be done via the integrated R package - cellHTS2. CellHTS2 produces quality control images and calculates a Z'factor value as quality score for the screen. CellHTS2 also calculates a z-score which can be used for hit selection.
The NRSC has developed a pipeline for the calculation of IC50 values. Data in screensaver are converted via an R-script into data-files which can be used in Graphpad Prism to calculate IC50, and to generate an image of the fitted curve.
Sun C, Wang L, Huang S, Heynen G, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems S, Zecchin D, Hober S, Bapje P, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels L, Beijersbergen R, Bardelli A, Nicolantonio F, Eggermont A, Bernards R. (2014) Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma.Nature. ;508(7494):118-122.
Sun C, Hober S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R (2014) Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.Cell Rep. Apr 10;7(1):86-93.
Bajpe PK, Heynen GJ, Mittempergher L, Grernrum W, de Rink IA, Nijkamp W, Beijersbergen RL, Bernards R, Huang S (2013) The corepressor CTBP2 is a coactivator of retinoic acid receptor / retinoid X receptor in retinoic acid signaling.Mol Cell Biol. Aug;33(16):3343-53.
Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-B receptor signaling.Cell. Nov 21;151(5):937-50.
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature. 26;483(7387):100-3.
Kuiken HJ, Egan DA, Laman H, Bernards R, Beijersbergen RL, Dirac AM. (2012) Identification of F-box only protein 7 as a negative regulator of NF-kappaB signaling.J Cell Mol Med. 10.1111/j.1582-4934.2012.01524.x.
Westerman BA, Braat AK, Taub N, Potman M, Vissers JH, Blom M, Verhoeven E, Stoop H, Gillis A, Velds A, Nijkamp W, Beijersbergen R, Huber LA, Looijenga LH, van Lohuizen M. (2011) A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation. J Exp Med. 19;208(13):2675-89.
Nijwening JH, Geutjes EJ, Bernards R, Beijersbergen RL. (2011) The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence. PLoS One. ;6(9):e25235. Epub 2011 Sep 27. PubMed PMID: 21980403; PubMed Central PMCID: PMC3181323.
Paul P, van den Hoorn T, Jongsma ML, Bakker MJ, Hengeveld R, Janssen L, Cresswell P, Egan DA, van Ham M, Ten Brinke A, Ovaa H, Beijersbergen RL, Kuijl C, Neefjes J. (2011) A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell. 15;145(2):268-83.
Nijwening JH, Kuiken HJ, Beijersbergen RL. (2011) Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.Cell Cycle. 1;10(3):380-6.
Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J. (2010) A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res. 1;16(1):99-108.
Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 23;142(2):218-29.
Mullenders J, Fabius AW, van Dongen MM, Kuiken HJ, Beijersbergen RL, Bernards R. (2010) Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res. Apr;8(4):592-603.
Albers HM, van Meeteren LA, Egan DA, van Tilburg EW, Moolenaar WH, Ovaa H. (2010) Discovery and optimization of boronic acid based inhibitors of autotaxin.J Med Chem. 8;53(13):4958-67.
Albers HM, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, Schuurman K, van Tellingen O, Morris AJ, Smyth SS, Moolenaar WH, Ovaa H. (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proc Natl Acad Sci U S A. 20;107(16):7257-62.
Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R, Del Sal G. (2010) BRD7 is a candidate tumour suppressor gene required for p53 function.Nat Cell Biol. Apr;12(4):380-9.
Mullenders J, Bernards R. (2009) Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.Oncogene. 17;28(50):4409-20.
Mullenders J, von der Saal W, van Dongen MM, Reiff U, van Willigen R, Beijersbergen RL, Tiefenthaler G, Klein C, Bernards R. (2009) Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.Clin Cancer Res. Sep 15;15(18):5811-9.
Hadrup SR, Toebes M, Rodenko B, Bakker AH, Egan DA, Ovaa H, Schumacher TN. (2009). High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol. 524:383-405.
Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. (2009) A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 2009;4(3):e4798.
Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 6;15(1):67-78.
Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, Bernards R, La Thangue NB. (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.Cancer Cell. 6;15(1):57-66.
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 15;68(22):9221-30.
Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, Bernards R, Eilers M. (2008) Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1.EMBO J. 5;27(21):2851-61.
Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G,Zhang L, Puré E, Agami R. (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. Feb;10(2):202-10.
Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den Nieuwendijk R, van den Eeden SJ, Geluk A, Poot A, van der Marel G, Beijersbergen RL, Overkleeft H, Ottenhoff TH, Neefjes J. (2007) Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1.Nature. 29;450(7170):725-30.
Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R.(2007)Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.EMBO J. 8;26(15):3699-708.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer Cell. Oct;12(4):395-402.
Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M. (2007) The ubiquitin-specific protease USP28 is required for MYC stability.Nat Cell Biol. Jul;9(7):765-74.
Bernards R, Brummelkamp TR, Beijersbergen RL. (2006) shRNA libraries and their use in cancer genetics.Nat Methods. Sep;3(9):701-6. Review.
Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL. (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.Nat Chem Biol. Apr;2(4):202-6.
Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC. (2005) Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells.Mol Cell. 9;20(5):673-85.
Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R. (2005) A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity.Cell. 17;121(6):849-58.
Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL. (2004) Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.Cold Spring Harb Symp Quant Biol. 69:439-45.
Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway.Nature. 25;428(6981):431-7.
Roderick Beijersbergen - group leader and head facility
Cor Lieftink - Bioinformaticus
Ben Morris - Technician
Martin de Rooij - Technician
Hier de link naar de carroussel
The committee consists of approximately 10 postdocs, representing various departments throughout the NKI.
Click here to read more details about the members.
|Fred van Leeuwen:|
"Postdocs fulfil a key role in the success of the research in our institute. As Dean for Postdoc Affairs, I work with the NKI postdoc committee and Human Resources to enable our postdocs to make the most out of their careers. We have just initiated and are further developing a training program to stimulate postdocs to take charge of their careers and develop themselves as highly skilled, innovative and independent researchers."
Postdoc training program
In collaboration with postdocs@NKI, the NKI Postdoc Dean and Human Resources are developing an educational program for postdocs. The goals of the program are to provide postdocs with the tools to take charge of their professional and personal development at the NKI, to ensure they make the most of their time at the NKI and to prepare them for the next step(s) in their career. The initial phase of the program has already begun and was officially launched at a Kick-off Event on the 27th of October 2014. Further modules are currently being developed and will begin in the second half of 2015.
Events and initiatives
On a yearly basis, we invite former NKI postdocs who have pursued interesting careers in and outside of academia to present at our NKI Career Evening. At this event, alumni give a short informal presentation about their career path to date and share experiences about their professional life. Following the presentations, we hold a mixer where attendees can interact with the speakers in a relaxed atmosphere. We aim for these events to be an opportunity for current postdocs to broaden their career outlook.
Seminars and workshops
We regularly organize a variety of informative seminars and workshops for the NKI postdoc community. In the recent past, these have included seminars on funding sources, communicating with the media, referencing software options as well as a workshop on technology transfer.
Grant writing courses
Since many postdocs will have to apply for grants or scholarships, postdocs@NKI have already organized three in-house grant writing courses for postdocs. These one-day courses help you to further develop your grant writing skills, focusing on developing a clear and concise writing style.
To keep the postdoc community well informed on any developments relevant to their work at the NKI as well as the activities that we organize, we produce a monthly email newsletter.
Postdocs@NKI have updated the NKI expat brochure for foreign employees. This brochure is a source of helpful information about moving to and working in the Netherlands. Topics such as housing, insurance, bank accounts and many more are addressed in the brochure. You can download the file here.